CAS 1440964-89-5

Formula: C20H15F3N8

InChI: InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3

InChI key: QHXLXUIZUCJRKV-UHFFFAOYSA-N

SMILES: CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F

Bozitinib

CAS: 1440964-89-5

Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.

Formula: C₂₀H₁₅F₃N₈

Purity: 99.16%

Color and Shape: Solid

Molecular weight: 424.3819

Ref: TM-T10585

Bozitinib

CAS: 1440964-89-5

Bozitinib

Formula: C₂₀H₁₅F₃N₈

Purity: ≥98%

Molecular weight: 424.38

Ref: 54-BUP02411

6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine

CAS: 1440964-89-5

Formula: C₂₀H₁₅F₃N₈

Purity: 98%

Color and Shape: Solid

Molecular weight: 424.3819

Ref: IN-DA01WTC0

Bozitinib (PLB-1001)

CAS: 1440964-89-5

Formula: C₂₀H₁₅F₃N₈

Molecular weight: 424.39

Ref: 4Z-B-268001

Bozitinib

CAS: 1440964-89-5

Formula: C₂₀H₁₅F₃N₈

Molecular weight: 424.4

Ref: BE-RMCB181001

Bozitinib

CAS: 1440964-89-5

6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine

Formula: C₂₀H₁₅F₃N₈

Purity: 98%

Molecular weight: 424.38

Ref: IN-DG00978663

Bozitinib (PLB-1001)

CAS: 1440964-89-5

Bosutinib is a CDK4/6 inhibitor that inhibits the activity of proteins that regulate cell division. Bosutinib has been shown to have anti-cancer properties by inhibiting the growth of cancer cells in preclinical models. Bosutinib also inhibits epidermal growth factor (EGF) and tumor necrosis factor (TNF). Bosutinib has been shown to have clinical benefit in patients with subcutaneous tumors, glioma, and other cancers. Bosutinib has not been evaluated in pregnant women or children and should be used only if potential benefits outweigh risks.

Formula: C₂₀H₁₅F₃N₈

Purity: Min. 95%

Molecular weight: 424.38 g/mol

Ref: 3D-QHC96489